التفاصيل البيبلوغرافية
| العنوان: |
Immunotherapy for Triple-Negative Breast Cancer: A Focus on Immune Checkpoint Inhibitors. |
| المؤلفون: |
Dua, Isha, Tan, Antoinette R. |
| المصدر: |
American Journal of Hematology/Oncology; May2017, Vol. 13 Issue 5, p20-27, 8p |
| مصطلحات موضوعية: |
ANTINEOPLASTIC agents, BREAST tumors, CELL physiology, CELL receptors, CELLULAR signal transduction, GENE expression, IMMUNOTHERAPY, METASTASIS, PROTEINS, TUMOR markers, TREATMENT effectiveness |
| مستخلص: |
Triple-negative breast cancer (TNBC) is a clinically heterogeneous and molecularly diverse disease. At present, chemotherapy is the standard treatment for early-stage and metastatic TNBC. The paucity of actionable targets, lack of targeted therapies, and relatively poor prognosis of patients with TNBC have created ample opportunity to evaluate novel treatment approaches. An improved understanding of the immunogenicity of TNBC has led to clinical studies of several immunotherapeutic agents. Early phase I trials with immune checkpoint inhibitors in TNBC report an overall response rate of up to 19% with durable clinical responses and a tolerable safety profile. The hope is that immunotherapy strategies will provide new therapeutic options for TNBC. This review focuses on the emerging data about immune checkpoint inhibitors in the treatment of TNBC. [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Hematology/Oncology is the property of Physicians' Education Resource, LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
